» Articles » PMID: 33863358

Radiomics for Prediction of Radiation-induced Lung Injury and Oncologic Outcome After Robotic Stereotactic Body Radiotherapy of Lung Cancer: Results from Two Independent Institutions

Overview
Journal Radiat Oncol
Publisher Biomed Central
Specialties Oncology
Radiology
Date 2021 Apr 17
PMID 33863358
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To generate and validate state-of-the-art radiomics models for prediction of radiation-induced lung injury and oncologic outcome in non-small cell lung cancer (NSCLC) patients treated with robotic stereotactic body radiation therapy (SBRT).

Methods: Radiomics models were generated from the planning CT images of 110 patients with primary, inoperable stage I/IIa NSCLC who were treated with robotic SBRT using a risk-adapted fractionation scheme at the University Hospital Cologne (training cohort). In total, 199 uncorrelated radiomic features fulfilling the standards of the Image Biomarker Standardization Initiative (IBSI) were extracted from the outlined gross tumor volume (GTV). Regularized models (Coxnet and Gradient Boost) for the development of local lung fibrosis (LF), local tumor control (LC), disease-free survival (DFS) and overall survival (OS) were built from either clinical/ dosimetric variables, radiomics features or a combination thereof and validated in a comparable cohort of 71 patients treated by robotic SBRT at the Radiosurgery Center in Northern Germany (test cohort).

Results: Oncologic outcome did not differ significantly between the two cohorts (OS at 36 months 56% vs. 43%, p = 0.065; median DFS 25 months vs. 23 months, p = 0.43; LC at 36 months 90% vs. 93%, p = 0.197). Local lung fibrosis developed in 33% vs. 35% of the patients (p = 0.75), all events were observed within 36 months. In the training cohort, radiomics models were able to predict OS, DFS and LC (concordance index 0.77-0.99, p < 0.005), but failed to generalize to the test cohort. In opposite, models for the development of lung fibrosis could be generated from both clinical/dosimetric factors and radiomic features or combinations thereof, which were both predictive in the training set (concordance index 0.71- 0.79, p < 0.005) and in the test set (concordance index 0.59-0.66, p < 0.05). The best performing model included 4 clinical/dosimetric variables (GTV-D, PTV-D, Lung-D, age) and 7 radiomic features (concordance index 0.66, p < 0.03).

Conclusion: Despite the obvious difficulties in generalizing predictive models for oncologic outcome and toxicity, this analysis shows that carefully designed radiomics models for prediction of local lung fibrosis after SBRT of early stage lung cancer perform well across different institutions.

Citing Articles

Machine learning in image-based outcome prediction after radiotherapy: A review.

Yuan X, Ma C, Hu M, Qiu R, Salari E, Martini R J Appl Clin Med Phys. 2024; 26(1):e14559.

PMID: 39556691 PMC: 11712300. DOI: 10.1002/acm2.14559.


A PET/CT radiomics model for predicting distant metastasis in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy: a multicentric study.

Yu L, Zhang Z, Yi H, Wang J, Li J, Wang X Radiat Oncol. 2024; 19(1):10.

PMID: 38254106 PMC: 10802016. DOI: 10.1186/s13014-024-02402-z.


Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis.

Shu Y, Xu W, Su R, Ran P, Liu L, Zhang Z Front Immunol. 2023; 14:1251645.

PMID: 37799725 PMC: 10547882. DOI: 10.3389/fimmu.2023.1251645.


The value of AI in the Diagnosis, Treatment, and Prognosis of Malignant Lung Cancer.

Wang Y, Cai H, Pu Y, Li J, Yang F, Yang C Front Radiol. 2023; 2:810731.

PMID: 37492685 PMC: 10365105. DOI: 10.3389/fradi.2022.810731.


Association of Multi-Phasic MR-Based Radiomic and Dosimetric Features with Treatment Response in Unresectable Hepatocellular Carcinoma Patients following Novel Sequential TACE-SBRT-Immunotherapy.

Ho L, Lam S, Zhang J, Chiang C, Chan A, Cai J Cancers (Basel). 2023; 15(4).

PMID: 36831445 PMC: 9954441. DOI: 10.3390/cancers15041105.


References
1.
Febbo J, Gaddikeri R, Shah P . Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Primer for Radiologists. Radiographics. 2018; 38(5):1312-1336. DOI: 10.1148/rg.2018170155. View

2.
Li H, Galperin-Aizenberg M, Pryma D, Simone 2nd C, Fan Y . Unsupervised machine learning of radiomic features for predicting treatment response and overall survival of early stage non-small cell lung cancer patients treated with stereotactic body radiation therapy. Radiother Oncol. 2018; 129(2):218-226. PMC: 6261331. DOI: 10.1016/j.radonc.2018.06.025. View

3.
Guckenberger M, Klement R, Kestin L, Hope A, Belderbos J, Werner-Wasik M . Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012; 85(4):1074-81. DOI: 10.1016/j.ijrobp.2012.09.016. View

4.
Guckenberger M, Aerts J, Van Schil P, Weder W . The American Society of Clinical Oncology-endorsed American Society for Radiation Oncology Evidence-Based Guideline of stereotactic body radiotherapy for early-stage non-small cell lung cancer: An expert opinion. J Thorac Cardiovasc Surg. 2018; 157(1):358-361. DOI: 10.1016/j.jtcvs.2018.09.107. View

5.
Liang B, Yan H, Tian Y, Chen X, Yan L, Zhang T . Dosiomics: Extracting 3D Spatial Features From Dose Distribution to Predict Incidence of Radiation Pneumonitis. Front Oncol. 2019; 9:269. PMC: 6473398. DOI: 10.3389/fonc.2019.00269. View